RFP
ESPR

Root Financial Partners’s Esperion Therapeutics ESPR Stock Holding History

Root Financial Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-44
Closed -$121 – 1280
2026
Q1 		$121 Buy
+44
New +$139 ﹤0.01% 3246

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Root Financial Partners's ESPR Position: Q2 2026 in Review

Root Financial Partners sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 44 shares — an estimated $121 sold.

Root Financial Partners first reported a position in ESPR in Q1 2026 and held it in 1 quarter. The position peaked at $121 in Q1 2026. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Root Financial Partners reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Root Financial Partners sold 44 Esperion Therapeutics shares in Q2 2026, an estimated $121.
  • Root Financial Partners first reported a position in Esperion Therapeutics in Q1 2026 and held it in 1 quarter.
  • Root Financial Partners's Esperion Therapeutics position peaked at $121 in Q1 2026.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.